Novartis unveils positive study data on Zolgensma gene therapy
Novartis has presented new study data on Zolgensma, its gene therapy treating spinal muscular atrophy (SMA). The data once again underscored the efficacy of this single-dose gene therapy in patients with SMA, according to a press release issued on Monday.
This content was published on
2 minutes
Keystone-SDA
العربية
ar
نوفارتيس السّويسريّة تكشف عن نتائج إيجابيّة لدراسة حول علاج زولجنسما الجّينيّ
The results of the SMART study added to what is known about the use of Zolgensma in patients who are older (1.5 – 9.1 years) and suffer more severely than the children treated in previous clinical trials.
In almost all cases, the motoric milestones of treated patients were maintained or even improved after 52 weeks. Many of these patients had switched therapies, having previously been treated with a different disease-modifying agent.
More
More
Swiss trade deal: Is India changing its tune on pharma patents?
This content was published on
Patent protection for the Swiss pharmaceutical industry has been a key sticking point in a free trade deal with India. What’s changed?
The SMART study is reportedly the first open-label clinical trial of Zolgensma to include previously treated patients. Novartis announced that it will present the data at the Muscular Dystrophy Association (MDA) conference, which is taking place in the US until March 6.
Adapted from German by DeepL/dkk/amav
This news story has been written and carefully fact-checked by an external editorial team. At SWI swissinfo.ch we select the most relevant news for an international audience and use automatic translation tools such as DeepL to translate it into English. Providing you with automatically translated news gives us the time to write more in-depth articles.
If you want to know more about how we work, have a look here, and if you have feedback on this news story please write to english@swissinfo.ch.
External Content
Your subscription could not be saved. Please try again.
Almost finished… We need to confirm your email address. To complete the subscription process, please click the link in the email we just sent you.
Switzerland says 90 countries and organisations will attend Ukraine peace summit
This content was published on
The Swiss-hosted conference is intended to lay the foundations for sustainable peace talks, in which Russia will also take part at a later date.
Hundreds of Saint Bernard dogs gather in Switzerland for world competition
This content was published on
Over a hundred Saint Bernards have descended on Martigny, in canton Valais to kick off the World Union of Saint Bernard Clubs competition.
If you want to start a conversation about a topic raised in this article or want to report factual errors, email us at english@swissinfo.ch.
Read more
More
Swiss trade deal: Is India changing its tune on pharma patents?
This content was published on
Patent protection for the Swiss pharmaceutical industry has been a key sticking point in a free trade deal with India. What’s changed?
You can find an overview of ongoing debates with our journalists here . Please join us!
If you want to start a conversation about a topic raised in this article or want to report factual errors, email us at english@swissinfo.ch.